Lipid transfers to HDL are predictors of precocious clinical coronary heart disease

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 502-505

  Maranhão, Raul C ^a   Freitas, Fatima R ^a   Strunz, Cãlia M ^a   Santos, Raul D ^a   Mansur, Alfredo J ^a   Mansur, Antônio P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Coronary artery disease (CAD); Free cholesterol; High density lipoprotein (HDL); Lipid transfer; Nanoparticles

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; NANOEMULSION; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED;

EID: 84355161409     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.011     Document Type: Article

References (26)

1. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009, 58:2711-2717.
2. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010, 21:312-318.
3. Tall A. Plasma lipid transfer proteins. Annu Rev Biochen 1995, 64:235-257.
4. Davidson M.H. Updateon CETP inhibition. J Clin Lipidol 2010, 4:394-398.
5. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effect of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
6. Lo Prete A.C., Dina C.H., Azevedo C.H., et al. In Vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids 2009, 44:917-924.
7. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. ClinChem 1972, 18:499-502.
8. Maranhão R.C., Cesar T.B., Pedroso-Mariani S.R., et al. Metabolic behavior in rats of a nonprotein microemulsion resembling LDL. Lipids 1993, 28:691-696.
9. Kwiterovich P.O. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000, 86:5 L-10 L.
10. Ferretti G., Bacchetti T., Négre-Salvayre A., Salvayre R., Dousset N., Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 2006, 184:1-7.
11. Puk C.G., Bocchi E.A., LoPrete A.C., Ferreira S.M., Stolf N.A., Maranhão R.C. Transfer of cholesterol and other lipids from a lipid nanoemulsion to high-density lipoprotein in heart transplant patients. J Heart Lung Transplant 2009, 28:1075-1080.
12. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Cur Opin Lipidol 2010, 21:229-238.
13. vonEckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001, 21:13-27.
14. Couto R.D., Dallan L.A., Lisboa L.A., Mesquita C.H., Vinagre C.G., Maranhão R.C. Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis. Lipids 2007, 42(5):411-418.
15. Dobiásov́ M., Strábrń J., Frohlich J.J. Relation of cholesterol esterification rate to the plasma distribution of high-density lipoprotein subclasses in normal and hypertensive women. Clin Invest Med 1995, 18:449-454.
16. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
17. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004, 110:1418-1423.
18. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
19. Vasan R.S., Pencina M.J., Robins S.J., Zachariah J.P., Kaur G., D'Agostino R.B., Ordovas J.M. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.
20. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010, 121:366-374.
21. McPherson R., Mann C.J., Tall A.R., et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 1991, 11:797-804.
22. Ikewaki K., Mabuchi H., Teramoto T., et al. Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects. Metabolism 2003, 52:1564-1570.
23. van Venrooij F.V., Stolk R.P., Banga J.D., et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003, 26:1216-1223.
24. Kappelle P.J., Perton F., Hillege H.L., Dallinga-Thie G.M., Dullaart R.P. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis 2011, 217(1):249-252.
25. Rashid S., Watanabe T., Sakaue T. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-426.
26. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005, 69:541-550.